New blood test may predict colorectal cancer recurrence

NCT ID NCT07492238

Ongoing Knowledge-focused Sponsor: Xiujuan Qu Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether a detailed blood test can help doctors see how well treatment is working and predict if cancer will come back in people with colorectal cancer that has spread to the liver or lungs (up to 5 spots). The test checks for tumor DNA, RNA, proteins, and other markers in the blood. Researchers will follow 120 patients for up to 24 months to see if the test results match with cancer progression or recurrence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Plasma multi-omics detection (ctDNA, cfRNA, proteomics, metabolomics)
What this could lead to: If successful, this could lead to a blood test that helps doctors personalize treatment and predict recurrence in colorectal cancer patients.
What could go wrong: This is an early-stage study with only 120 participants, so results may not apply to everyone. The tests are experimental and not yet proven to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Locations

The First Affiliated Hospital of China Medical University

Shenyang, Liaoning, 110001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.